Sirna to Manufacture Aptamers for Archemix, Posts Q2 Financials
Sirna Therapeutics said this week that it has signed an exclusive, four-year deal to manufacture all of Archemix’s aptamers used through phase IIa clinical development. Sirna has additionally granted a worldwide, non-exclusive, perpetual license to its aptamer manufacture and commercialization intellectual property to Archemix.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
